SEC Form 4 · accession 0001140361-18-009666
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles N York II
Officer — Chief Financial Officer and VP
Period of report
Feb 20, 2018
Accepted (ET)
Feb 22, 2018 · 6:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $6.31 | Feb 20, 2018 | A | 92,100 | A | — | Feb 19, 2028 | Common Stock | 92,100 | 92,100 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.